>>Description of the research protocol "Registre"

Prospective Registry of Inclusig (Ponatinib) used in clinical practive for the treatment of patients with chronic myeloid leukemia or Ph+ acute lymphoblastic Leukemia in Belgium.
Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Hématologie
Brugmann identifier : Registre
EudraCT identifier : B322201629750


Involved department : Hemato-oncology
Principal investigator : Nifosi/Efira
Sponsor : InScienesBen
Contact : Clinical Research Unit

>This protocol was approved by the KU Leuven ethics committee.